Citius Oncology (CTOR) Equity Average (2022 - 2026)

Citius Oncology's Equity Average history runs 5 years deep, the most recent figure standing at $46.8 million for Q1 2026.

• In Q1 2026, Equity Average rose 21.77% year-over-year to $46.8 million; the TTM figure through Mar 2026 stood at $46.8 million (up 21.77% YoY), while the FY2025 annual figure was $45.5 million, up 32.15% from the prior year.
• Equity Average was $46.8 million for Q1 2026 at Citius Oncology, down from $51.6 million in the prior quarter.
• In the past five years, Equity Average ranged from a high of $51.6 million in Q4 2025 to a low of $97809.0 in Q2 2023.
• Historically, Equity Average has averaged $26.6 million across 5 years, with a median of $24.1 million in 2023.
• The sharpest annual moves came in 2023 and 2024: Equity Average fell 29.58% in 2023, then jumped 18751.83% in 2024.
• A 5-year view of Equity Average shows it stood at $18.3 million in 2022, then soared by 31.81% to $24.1 million in 2023, then jumped by 81.16% to $43.7 million in 2024, then gained by 18.13% to $51.6 million in 2025, then declined by 9.29% to $46.8 million in 2026.
• The last three Equity Average figures came in at $46.8 million (Q1 2026), $51.6 million (Q4 2025), and $38.6 million (Q3 2025), per Business Quant data.